Abstract
The simultaneous administration of an oral dose and intravenous tracer dose, as a method to determine bioavailability, was examined by means of computer simulation for drugs exhibiting Michaelis-Menten type elimination. A physiological pharmacokinetic model parameterized for man and including first-order absorption and elimination solely from the liver was employed. This tracer method provided good estimates of the true availability, with an error of 6% or less, over a wide range of dosing and dispositional conditions. Poorer estimates were noted when large doses of drugs with very short half-lives were considered. This poor performance was improved by administering the intravenous tracer at some time after the oral dose but an a prioribasis for establishing this time was not apparent. The tracer method, therefore, appears to be a robust means of assessing, in man, oral bioavailability in the presence of Michaelis-Menten type elimination for drugs characterized by the general properties of the physiological model employed and with half-lives in excess of approximately 40 min. These findings together with the statistical power and simplicity of performance of the tracer method indicate that it is a valid technique for the assessment of bioavailability under a wide range of kinetic conditions.
Similar content being viewed by others
References
J. M. Strong, J. S. Dutcher, W. K. Lee, and A. J. Atkinson. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.Clin. Pharmacol Ther. 18:613–622 (1975).
M. Eichelbaum, A. Somogyi, G. E. von Unruh, and H. J. Denglet. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D, L-verapamil using stable isotope-labeled verapamil.Eur. J. Pharmacol. 19:133–137 (1981).
Y. Shinohara, S. Baba, Y. Kasuya, G. Knapp, F. R. Pelsor, V. P. Shah, and I. L. Honigberg. Stable-isotope methodology in the bioavailability study of 17-methyltestosterone using gas chromatography-mass spectrometry.J. Pharm. Sci. 75:161–164 (1986).
D. M. Kornhauser, A. J. J. Wood, R. E. Vestal, G. R. Wilkinson, R. A. Branch, and D. G. Shand. Biological determinants of propranolol disposition in man.Clin. Pharmacol. Ther. 23:165–174 (1978).
A. J. J. Wood, K. Carr, R. E. Vestal, S. Belcher, G. R. Wilkinson, and D. G. Shand. Direct measurement of propranolol bioavailability during accumulation to steady-state.Br. J. Clin. Pharmacol. 6:345–350 (1978).
H. d'A. Heck, S. E. Buttrill, N. W. Flynn, R. L. Dyer, M. Anbar, T. Cairns, S. Dighe, and B. E. Cabana. Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests.J. Pharmacokin. Biopharm. 7:233–248 (1979).
Y. Kasuya, K. Mamada, S. Baba, and M. Matsukura. Stable-isotope methodology for the bioavailability study of phenytoin during multipledosing regimens.J. Pharm. Sci. 74:503–507 (1985).
J. A. Waschek, G. M. Rubin, T. N. Tozer, R. M. Fielding, W. R. Couet, D. J. Effeney, and S. M. Pond. Dose-dependent bioavailability and metabolism of salicylamide in dogs.J. Pharmacol. Exp. Ther. 230:89–93 (1984).
M. Rowland. Effect of some physiologic factors on bioavailability of oral dosage forms. In J. Swarbrick (ed.),Current Concepts in the Pharmaceutical Sciences: Dosage Form Design and Bioavailability, Lea & Febiger, Philadelphia, 1973, pp. 181–222.
G. M. Rubin and T. N. Tozer. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.J. Pharmacokin. Biopharm. 12:437–450 (1984).
L. Martis and R. H. Levy. Bioavailability calculations for drugs showing simultaneous first-order and capacity limited elimination kinetics.J. Pharmacokin. Biopharm. 1:283–294 (1973).
W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability.J. Pharmacokin. Biopharm. 4:327–336 (1976).
P. J. Wedlund and G. R. Wilkinson. Hepatic tissue binding and the oral first-pass effect.J. Pharm. Sci. 73:422–425 (1984).
K. S. Pang and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred“ model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–653 (1977).
R. C. Boston, P. C. Greif, and M. Berman. Conversational SAAM: an interactive program for kinetic analysis of biological systems.Comp. Prog. Biomed. 13:111–119 (1981).
W. L. Chiou. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule for the calculation of the area under the plasma concentrationtime curve.J. Pharmacokin. Biopharm. 6:539–546 (1978).
R. A. Upton and R. L. Williams. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.J. Pharmacokin. Biopharm. 14:365–380 (1986).
A. Richens. Clinical pharmacokinetics of phenytoin.Clin. Pharmacokin. 4:153–169 (1979).
G. Levy, T. Tsuchiya, and L. P. Amsel. Limited capacity of salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.Clin. Pharmacol. Ther. 13:258–268 (1972).
L. J. Lesko. Nonlinear kinetics and theophylline elimination. In L. Z. Benet, N. Massoud, and J. G. Gambertoglio (eds),Pharmacokinetic Basis for Drug Treatment Ch. 17, Raven Press, New York, 1984 pp. 321–332.
J. G. Wagner. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.Clin. Pharmacol. Ther. 37:481–487 (1985).
W. J. Westlake. Statistical aspects of comparative bioavailability trials.Biometrics 35:273–280 (1979).
D. J. Chodos and A. R. DiSanto.Basics of Bioavailability, The Upjohn Company, Kalamazoo, MI, 1974.
K. S. Albert and C. M. Gernaat. Pharmacokinetics of ibuprofen.Am. J. Med. 77:40–46 (1984).
T. Terasaki, Y. Sugiyama, T. Iga, Y. Sawada, and M. Hanano. Theoretical consideration of drug distribution kinetics in a noneliminating organ: Comparison between a “homogeneous (well-stirred)” model and “nonhomogeneous (tube)” model.J. Pharmacokin. Biopharm. 13:265–288 (1985).
Author information
Authors and Affiliations
Additional information
This work was supported in part by U.S. Public Health Service grant GM 31304.
Rights and permissions
About this article
Cite this article
Hall, S.D., McAllister, C.B. & Wilkinson, G.R. The assessment of bioavailability in the presence of nonlinear elimination. Journal of Pharmacokinetics and Biopharmaceutics 16, 263–278 (1988). https://doi.org/10.1007/BF01062137
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062137